# Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069

> **NCT01989520** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 36 (actual)

## Conditions studied

- Uncontrolled and Persistent Asthma

## Interventions

- **DRUG:** Phase IIb formulation
- **DRUG:** Putative phase III formulation
- **DRUG:** Slow dissolution variant 1
- **DRUG:** Slow dissolution variant 2
- **DRUG:** Test treatment E

## Key facts

- **NCT ID:** NCT01989520
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2015-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01989520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01989520, "Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01989520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*